Acetylaminosuccinic acid (Acidum acetylaminosuccinicum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Genotoninizing agents and adaptogens

Included in the formulation
  • Cogitum
    solution inwards 
    SANOFI RUSSIA, CJSC    
    • АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:
    Acetylaminosuccinic acid is a synthetic analogue of aspartic acid, a replaceable amino acid, mainly contained in the tissues of the central nervous system.

    Aspartic acid has a pronounced immunomodulatory effect (promotes the acceleration of the formation of immunoglobulins and antibodies), and also takes part in the synthesis deoxyribonucleic acid and ribonucleic acid, improves physical endurance and normalizes the processes of inhibition and excitation in the central nervous system.

    Aspartic acid is involved in a number of metabolic processes, in particular, regulates carbohydrate metabolism by stimulating the transformation of carbohydrates into glucose and the subsequent creation of glycogen stores.

    Along with glycine and glutamic acid, aspartic acid is a neurotransmitter in the central nervous system, stabilizes the processes of nervous regulation, improves metabolic processes in the brain tissues and exerts some psychostimulating effect.

    In addition, aspartic acid has a pronounced hepatoprotective effect, reduces the negative effect of radiation on the body, and also stimulates the elimination of neurotoxic ammonia from the body.

    In this way, acetylamino succinic acid has a stabilizing effect on the processes of nervous regulation. Possesses some psychostimulating and nootropic activity.

    Pharmacokinetics:
    Data on the pharmacokinetics of the drug are not enough. In organism acetylamino succinic acid completely metabolized to water and carbon dioxide, not cumulated.

    Indications:
    Nervous depletion with mild depression, an adjuvant in the treatment of antidepressants, as part of the complex therapy of asthenic syndrome.

    ICD-10

    V.F30-F39.F32.0   Depressive episode of mild

    V.F40-F48.F48.0   Neurasthenia

    XVIII.R50-R69.R53   Malaise and fatigue

    Contraindications:Hypersensitivity to acetylaminosuccinic acid, pregnancy (insufficient clinical data), children under 7 years of age (no clinical data).
    Carefully:Long-term effectiveness and safety have not been studied.The expediency of use is not determined by large-scale clinical studies.
    Pregnancy and lactation:
    Category of recommendations for Food and Drug Administration (US Food and Drug Administration) not determined.

    Adequate and well-controlled studies on humans and animals have not been conducted. There is no information on the penetration of the drug into breast milk.

    Dosing and Administration:
    Inside - in undiluted form or with a small amount of water. Dose is administered individually. The average dose is 750 mg (the contents of 3 ampoules: 2 in the morning and 1 at night) per day. The maximum daily dose is not determined. The average duration of treatment in children and adults is 3 weeks.

    If, for any reason, one or more doses of the drug were missed, the treatment can be continued without the need for a secondary dose adjustment. Treatment can also be abruptly discontinued without any serious consequences for the patient.

    Side effects:Allergic reactions are possible.
    Overdose:There is no evidence of an overdose of the drug.
    Interaction:No interaction with other drugs was noted.
    Special instructions:The drug can be used in elderly patients. It is unlikely that the drug may affect the ability to drive vehicles, mechanisms or to engage in other potentially hazardous activities. The morning reception of the drug is most preferable.
    Instructions
    Up